Abstract 2646
Background
Genotyping on cfDNA offers potential advantages in clinical practice for pt selection and serial monitoring of treatment (Tx) efficacy. Clinical relevance of sequential RASmut in cfDNA at different time points during 1L of pt with RASwt solid biopsies (SB) was evaluated.
Methods
Prospective, multi-center study in mCRC pt with RASwt according to SB and treated following standard practice. Liquid biopsies (LB) were collected before starting 1L, at 20 (± 2) weeks (w) and at disease progression (PD). Beaming PCR was used for cfDNA analysis; 3 mutant allele fraction (MAF) cutoffs were considered: 1%, 0.1% & 0.02%.
Results
Median progression-free survival (PFS) was 11.7 months (m) (9.9-13.0) (n = 102). There were no differences in the overall response rate (ORR) according to baseline LB at any cut off, being at MAF 0.02%: 78.7% (68.2- 87.1) in RASwt pt (n = 80) vs 61.5% (31.6 - 86.1) in RASmut pt (n = 13) (OR: 2.32; p = 0.180). MAF was not correlated with total cfDNA levels (p = 0.957). The % of mut cfDNA pt varied along time, with the smallest % at 20 w (Table). There were no emergent mutations at 20 w. Ten pt wt according to baseline LB presented mutations at PD. ORR was 76.9% (63.2 - 87.5) in pt always wt (n = 52) vs 76.2% (52.8 - 91.8) in pt with mut cfDNA at any time point (n = 21) (p = 1.0). There were also no differences in PFS between these 2 groups of pt: 13.0 m (10.9 - 15.4) vs 11.4 m (7.1 – 13.7) at MAF 0.02% (p = 0.095).Table:
531PD
MAF≥1% | MAF≥0.1% | MAF≥0.02% | |
---|---|---|---|
Baseline | 3 (2.9%) n = 102 | 6 (5.9%) n = 102 | 14 (13.7%) n = 102 |
PFS RASwt: 11.7 m (9.9-13.0) RASmt: NR (5.9-NR) (p = 0.689) | PFS RASwt: 11.7 m (9.9-13.1) RASmt: 7.8 m (5.9-NR) (p = 0.662) | PFS RASwt: 11.7 m (9.9-13.1) RASmt: 11.4 m (5.9-18.5) (p = 0.495) | |
20 ± 2 weeks | 0 (0%) n = 76 | 3 (4.0%) n = 76 | 4 (5.3%) n = 76 |
PD | 1 (2.0%) n = 49 | 9 (18.4%) n = 49 | 12 (24.5%) n = 49 |
Proportions of mutated patients based on the number of samples analysed at each time point and progression-free survival (PFS) according to the baseline plasma sample PD Progression of the disease; MAF: Mutant Allele Fraction; NR: not reached
Conclusions
RAS mutational status assessed in cfDNA before starting 1L or sequentially during P+CT Tx in pt with RASwt SB was not a significant predictor of PFS and ORR in none of the cutoffs considered, although in RASmut pt clinical results tended to increase as MAF decreased. The highest proportion of mutated pt was observed at PD, which may be linked to the emergence of resistance. Mutated cfDNA by itself did not predict a lack of clinical benefit to CT and P in our study.
Clinical trial identification
Editorial acknowledgement
Marta Muñoz-Tudurí (TFS, S.L.).
Legal entity responsible for the study
Amgen S.A.
Funding
Amgen S.A.
Disclosure
M. Valladares-Ayerbes: Honoraria (self): Amgen, Merck, Roche, Servier, Bayer, Bristol-Myers; Advisory / Consultancy: Merck, Sanofi, Amgen; Speaker Bureau / Expert testimony: Roche, Servier, Bayer; Research grant / Funding (self): Roche; Travel / Accommodation / Expenses: Merck, Servier, Amgen, Roche. J.M. Viéitez: Travel / Accommodation / Expenses, attendance at conferences: Amgen, Roche, Servier; Research grant / Funding (self): Roche, Amgen. J.J. Cruz-Hernández: Honoraria (self): Amgen, AstraZeneca, Bristol-Myers Squibb, Novartis, Pfizer, Roche Farma; Advisory / Consultancy, Advisory Board: Bristol-Myers Squibb, Merck, MSD, Roche Farma, Pfizer, Janssen Cilag; Advisory / Consultancy, Consulting: Roche Farma. M. Llanos: Advisory / Consultancy, collaboration in lectures: Servier, Roche, Ipsen, Merck, Bristol, Sanofi, Eisai; Advisory / Consultancy: Amgen. A. Lloansí Vila: Shareholder / Stockholder / Stock options, employee and stakeholder of Amgen S.A: Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
1057 - TRIUMPH: Primary Efficacy of a Phase II Trial of Trastuzumab (T) and Pertuzumab (P) in Patients (pts) with Metastatic Colorectal Cancer (mCRC) with HER2 (ERBB2) Amplification (amp) in Tumor Tissue or Circulating Tumor DNA (ctDNA): A GOZILA Sub-study
Presenter: Yoshiaki Nakamura
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
4795 - Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial
Presenter: John Strickler
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
2951 - Impact of clonality and DNA repair mutations on plasma tumor mutation burden (pTMB) and immunotherapy efficacy in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) in CCTG CO.26
Presenter: Jonathan Loree
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
3298 - Early identification of treatment effect by methylated circulating tumor DNA in metastatic colorectal cancer
Presenter: Caroline Thomsen
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
5073 - Association between transit-amplifying signature and outcomes of patients treated with anti-epidermal growth factor receptor (EGFR) therapy in colorectal cancer
Presenter: Elisa Fontana
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
5828 - Pre-operative FOLFOX chemotherapy in advanced colon cancer: pathology analysis of the FOxTROT trial
Presenter: Nick West
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
3464 - BACCI: A Phase II Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Capecitabine (C) Bevacizumab (B) plus Atezolizumab (A) or Placebo (P) in Refractory Metastatic Colorectal Cancer (mCRC): An ACCRU Network Study
Presenter: Niharika Mettu
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
3857 - Phase II Study of Pertuzumab and Trastuzumab-emtansine (T-DM1) in Patients with HER2-positive Metastatic Colorectal Cancer: the HERACLES-B (HER2 Amplification for Colo-rectaL cancer Enhanced Stratification, cohort B) Trial
Presenter: Andrea Sartore-Bianchi
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
5756 - Randomized phase II study of CAPTEM versus FOLFIRI in RAS mutated, MGMT methylated metastatic colorectal cancer (mCRC): final analysis, tumor biomarkers and methylated ctDNA
Presenter: Filippo Pietrantonio
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
Poster Discussion – Gastrointestinal tumours, colorectal - Invited Discussant LBA35, LAB36, 526PD and 527PD
Presenter: Ramon Salazar
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Slides
Webcast